X0203 3 2010-10-21 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001197540 FISHERMAN JASON S 75 STATE STREET, 29TH FLOOR BOSTON MA 02109 1 0 0 0 Common Stock 13 I See Footnote Series A Convertible Preferred Stock Common Stock 3565 I See Footnote Series B Convertible Preferred Stock Common Stock 1245 I See Footnote Senior Subordinated Convertible Promissory Notes 7.60 2011-12-31 Common Stock 2286 I See Footnote Reflects a 1-for-2.4417 reverse stock split effected on October 19, 2010 in connection with the Issuer's initial public offering. Shares are indirectly beneficially owned as a limited partner of Advent Partners HLS III Limited Partnership. The Series A Convertible Preferred Stock (the "Series A Shares") and the Series B Convertible Preferred Stock (the "Series B Shares") are convertible, in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation, at any time after the issuance of such shares, at the holder's election. The Series A Shares and the Series B Shares, including all accrued and unpaid interest thereon, will convert automatically into Common Stock without payment of any additional consideration, upon the closing of the Issuer's initial public offering and do not have an expiration date. The Series A Shares will convert on a 1-for-0.38701117412 basis and the Series B Shares will convert on a 1-for-0.61027657931 basis. Reflects $15,753,09 aggregate principal and interest amount of senior subordinated convertible promissory notes (the "Convertible Notes",) dated September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010, and October 1, 2010. The outstanding principal and accrued and unpaid interest on these Convertible Notes shall automatically be converted into shares of common stock upon the closing of the Issuer's initial public offering. The outstanding principal and accrued and unpaid interest on these Convertible Notes shall automatically be converted into shares of common stock upon the closing of the Issuer's initial public offering at $7.60 per share, 80% of the Issuer's initial public offering price per share. /s/ Jarlyth H. Gibson, Attorney-in-Fact 2010-10-22